Praveen P Nekkar Rao

Prof. Praveen P Nekkar Rao

School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada
orcid
Associate Professor

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2008 in Journal of Pharmacy & Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
Praveen P Nekkar RaoPraveen P Nekkar Rao
Praveen P Nekkar Rao
EKEdward E. Knaus
Edward E. Knaus
Purpose. NSAIDs constitute an important class of drugs with therapeutic applications that have spanned several centuries. Treatment of inflammatory conditions such as rheumatoid arthritis (RA) and osteoarthritis (OA) starting from the classic drug aspirin to the recent rise and fall of selective COX-2 inhibitors has provided an enthralling evolution. Efforts to discover an ultimate magic bullet to treat inflammation continues to be an important drug design challenge. This review traces the origins of NSAIDs, their mechanism of action at the molecular level such as cyclooxygenase (COX) inhibition, development of selective COX-2 inhibitors, their adverse cardiovascular effects, and some recent developments targeted to the design of effective anti-inflammatory agents with reduced side effects. Methods. Literature data is presented describing important discoveries pertaining to the sequential development of classical NSAIDs and then selective COX-2 inhibitors, their mechanism of action, the structural basis for COX inhibition, and recent discoveries. Results. A brief history of the development of NSAIDs and the market withdrawal of selective COX-2 inhibitors is explained, followed by the description of prostaglandin biosynthesis, COX isoforms, structure and function. The structural basis for COX-1 and COX-2 inhibition is described along with methods used to evaluate COX-1/COX-2 inhibition. This is followed by a section that encompasses the major chemical classes of selective COX-2 inhibitors. The final section describes briefly some of the recent advances toward developing effective anti-inflammatory agents such as nitric oxide donor NO-NSAIDs, dual COX/LOX inhibitors and anti-TNF therapy. Conclusions. A great deal of progress has been made toward developing novel anti-inflammatory agents. In spite of the tremendous advances in the last decade, the design and development of a safe, effective and economical therapy for treating inflammatory conditions still presents a major challenge.

1 August 2001 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AHAmgad G. Habeeb
Amgad G. Habeeb
Praveen P Nekkar RaoPraveen P Nekkar Rao
Praveen P Nekkar Rao
EKEdward E. Knaus
Edward E. Knaus

1 May 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TMTarek M M Mohamed
Tarek M M Mohamed
ASArash Shakeri
Arash Shakeri
Praveen P Nekkar RaoPraveen P Nekkar Rao
Praveen P Nekkar Rao

1 August 2001 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AHAmgad G. Habeeb
Amgad G. Habeeb
Praveen P Nekkar RaoPraveen P Nekkar Rao
Praveen P Nekkar Rao
EKEdward E. Knaus
Edward E. Knaus

24 March 2015 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
Praveen P Nekkar RaoPraveen P Nekkar Rao
Praveen P Nekkar Rao
TMTarek Mohamed
Tarek Mohamed
KTKaran Teckwani
Karan Teckwani
GTGary Tin
Gary Tin

21 May 2005 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CVCarlos Velázquez
Carlos Velázquez
Praveen P Nekkar RaoPraveen P Nekkar Rao
Praveen P Nekkar Rao
EKEdward E. Knaus
Edward E. Knaus